SAN JOSE, Calif., March 17, 2026 /PRNewswire/ -- PEGATRON, a globally recognized total server solutions provider, will showcase its latest AI infrastructure platforms at NVIDIA GTC 2026. Powered by NVIDIA Vera Rubin NVL72, NVIDIA HGX Rubin NVL8, and NVIDIA RTX PRO™ 6000 Blackwell Server Edition GPUs, these platforms deliver breakthrough performance, rack-scale integration, and liquid-cooled efficiency for hyperscale and enterprise AI deployments.
NVIDIA Vera Rubin NVL72 Rack-Scale AI Supercomputer
The Pegatron RA4803-72N3, powered by NVIDIA Vera Rubin NVL72, is a liquid-cooled rack-scale AI supercomputer designed for next-generation workloads. Integrating 72 NVIDIA Rubin GPUs, 36 NVIDIA Vera CPUs, NVIDIA NVLink 6 scale-up networking, NVIDIA ConnectX-9 SuperNICs, NVIDIA BlueField-4 DPUs, and NVIDIA Spectrum-X Ethernet networking, the solution delivers 3.6 EFLOPS inference performance, 260 TB/s bandwidth, and 20.7 TB HBM4 memory. Compared with NVIDIA Blackwell architecture, it trains mixture-of-experts models using one-fourth the GPUs, reduces inference costs by up to 10X, and achieves 5X higher throughput—dramatically improving performance per watt, lowering footprint, and optimizing total cost of ownership for AI factories.
Powering Rack-Scale AI with Up to 9 HGX Rubin NVL8 Systems
The Pegatron AS210-2T1-8H3 is a 2U liquid-cooled server based on NVIDIA HGX Rubin NVL8 and dual Intel Xeon 6 processors, designed to accelerate enterprise AI workloads. Leveraging NVIDIA Rubin GPUs, NVLink 6, ConnectX-9 SuperNICs, BlueField-4 DPUs, and Spectrum-X Ethernet networking, it delivers optimized AI and HPC performance. Scaling up to rack-level AI infrastructure, the RA4800-64H3 and RA4800-72H3 deliver ultra-high-density performance in liquid-cooled rack architectures. The RA4800-64H3 integrates eight 2U systems per rack, supporting up to 64 NVIDIA HGX Rubin GPUs and 16 Intel Xeon 6 processors, while the RA4800-72H3 integrates up to nine 2U systems in a 48U rack—scaling to 72 GPUs and 18 CPUs to enable unprecedented compute density and faster time-to-insights for large-scale AI workloads.
NVIDIA RTX PRO 6000 and NVIDIA RTX PRO™ 4500 Blackwell Server Edition GPUs for AI and Digital Workloads
Pegatron's servers powered by NVIDIA RTX PRO Blackwell Server Edition GPUs enable generative AI, data processing, simulation, and visualization workloads with exceptional efficiency.
The MS303-2A1G-P60 supports up to four liquid-cooled NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs and dual AMD EPYC™ 9005 processors. Featuring ultra-fast 96GB GDDR7 memory, it delivers high-density, multi-workload performance and reliability for mission-critical deployments.
Complementing this platform, the AS205-2T1 supports up to four NVIDIA RTX PRO 4500 Blackwell Server Edition GPUs with fifth-generation Tensor Cores and 32GB GDDR7 memory in a single-slot form factor, along with dual Intel Xeon 6 processors. This power-efficient design provides scalable, cost-effective AI acceleration for enterprise and edge applications.
"Building AI factories requires more than powerful hardware—it demands deep system integration expertise and execution at scale," said Dr. James Shue, SVP & CTO of Pegatron. "With the launch of our platforms powered by NVIDIA Vera Rubin NVL72 and NVIDIA HGX Rubin NVL8, combined with proven deployment capabilities, Pegatron enables customers to move from infrastructure build-out to AI production faster, more efficiently, and with greater operational confidence."
Explore the Next Generation of AI
Visit Pegatron Booth #830 at NVIDIA GTC 2026 to discover how integrated rack-scale systems, liquid cooling innovation, and factory-scale manufacturing are powering the next wave of AI infrastructure.
For more information, please visit PEGATRON SVR website and follow us on LinkedIn and YouTube.
PEGATRON Corporation (hereafter referred to as "PEGATRON"), with abundant product development experience and vertically integrated manufacturing, is committed to providing clients with innovative design, systematic production, and manufacturing services to comprehensively and efficiently satisfy all our customers' needs.
Drawing on accumulated experience in server design, manufacturing, and deployment, Pegatron focuses on developing a variety of state-of-the-art servers including liquid-cooled/air-cooled server solutions based on x86 and ARM architectures, racks, and AI clusters, that meet the requirements of present and future Cloud Service Providers' data centers, as well as enterprise-grade data centers.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Collaboration expands research of new delivery platform beyond liver tissues supporting potential preclinical development and strengthens Singapore's position as a biomedical innovation hub
The global oligo therapeutics market exceeded $7 billion in 2025 and is projected to reach $18 billion by 2030¹, driven by clinically validated DNA- and RNA-based therapies that continue to face analytical challenges beyond liver-targeted delivery².
Under this agreement, the collaboration will focus on developing end-to-end analytical and preparative workflows to support ligand-conjugated strategies, a new platform designed to extend oligo delivery beyond the liver tissues, unlock access to extrahepatic tissues and expand the therapeutic addressable market.
"Lipid-conjugated oligonucleotides represent a promising next frontier in nucleic acid therapeutics, particularly in expanding beyond hepatic delivery. Working with strategic partners like Agilent allows us to tighten the value chain from research to clinic, accelerating the development of next-generation oligo therapeutics that address areas of significant unmet medical need," said Dr Mohamed ElSayed, Executive Director of Nucleic Acid Therapeutics Initiative (NATi).
"As oligo-based therapies continue to transform precision medicine, the ability to reliably analyze and purify complex conjugates becomes increasingly critical. Our priority remains to help existing and new biopharma customers accelerate new discoveries through research advancement. This collaboration is yet another example of our commitment to investing in high-growth markets while delivering on Agilent's mission of improving the quality of life," said Bharat Bhardwaj, Vice President of APAC Sales at Agilent.
The agreement includes structured training and access to advanced analytical capabilities at Agilent's Global Solution Development Center (GSDC) in Singapore, along with a broader suite of Agilent analytical instruments.
With more than 25 years of investment in Singapore, Agilent has grown its local presence to about 600 scientists, engineers and skilled professionals and operates an 860,000-square-foot manufacturing facility recognized by the World Economic Forum. The expanding footprint underscores Agilent's long-term commitment to building local scientific capabilities, talent development and strengthening Singapore's position as a leading biomedical innovation hub for the region and beyond.
About Agilent Technologies
Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
About the Nucleic Acid Therapeutics Initiative (NATi)
The Nucleic Acid Therapeutics Initiative (NATi) is a national platform based in Singapore and hosted by Agency for Science, Technology and Research (A*STAR), dedicated to advancing RNA medicines from discovery to early clinical development. NATi combines deep scientific expertise with scalable technology platforms to generate differentiated nucleic acid therapeutic assets. Through close collaboration with industry and public partners, NATi drives translation, enables commercialisation, and strengthens Singapore's capabilities in next-generation therapeutics. Learn more at www.nati.sg.
AlShaer D, Al Musaimi, O, Albericio F, de la Torre BG. 2025 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). 2026 Jan 30;19(2):244. doi: 10.3390/ph19020244. PMID: 41754785; PMCID: PMC12943124.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
